AstraZeneca Expands Lymphoma Pipeline With TeneoTwo Acquisition
Enters Crowded Bispecific Field
AstraZeneca has bought TeneoTwo and its bispecific asset TNB-486 to enlarge its hemato-oncology pipeline but the UK major is still a long way off being a key player in the field.
You may also be interested in...
Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.
Genmab may only recently have launched its first commercial operations with Tivdak, but is stepping up to co-market epcoritamab with AbbVie against the might of Roche in the new CD20xCD3 field.
Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.